ClinicalTrials.gg
CompletedNCT01185353Updated Jun 16, 2017Results posted

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

A Phase 2 interventional study of LY3009104 and Placebo in Arthritis, Rheumatoid, sponsored by Eli Lilly and Company. Completed at 68 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-06-16.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
11th of 23
301 · median 290
Started
2010
the only one that year
Phase 2
3 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 2nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the safety and efficacy of LY3009104 in participants with Rheumatoid Arthritis (RA).

Read the detailed description

This study consists of the following:

  • Screening period: 4 to 28-days
  • Part A: a 12-week blinded, placebo controlled treatment period
  • Part B: a 12-week blinded extension period
  • Part C: an optional 52-week open-label extension period
  • Part D: an additional optional 52-week open-label extension period
  • Follow up period: 28 days
03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • Rheumatoid Arthritis
  • RA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have active RA
  • Must regularly use methotrexate (MTX) for at least 12 weeks before your participation in this study
  • Must have American College of Rheumatology (ACR) functional class I, II, or III
  • Must have C-reactive protein (CRP) measurement > 1.2 times (ULN) or Erythrocyte Sedimentation Rate (ESR) > ULN [28 millimeters/hour (mm/hr)]
  • Have laboratory values that in the opinion of the investigator do not pose an unacceptable risk to the participants if study drug would be administered
  • Must have venous access sufficient to allow blood sampling as per the protocol
  • Must be reliable and willing to be available for the duration of the study and are willing to follow study procedures
  • Must be able to read, understand, and give written approved by Lilly or its designee and the ethical review board (ERB) governing the site
  • Male participants: agree to use 2 forms of highly effective methods of with female partners of during the study
  • If you are a woman and you could become pregnant during this study, you must talk to the study doctor about birth control. You are required to use 2 forms of highly effective methods of birth control to avoid getting pregnant during the study
  • If you are a woman, you must be at least 45 years of age and have not menstruated for the last 12 months
  • If you are a woman between 40 and 45 years of age, test negative for pregnancy, and have not menstruated during the last 12 months only, you must have an additional blood test
  • For participants receiving , you must be on a dose not to exceed 10 mg of prednisone daily (or equivalent) and have been on the same dosing regimen for at least 6 weeks prior to randomization
  • Continue to meet inclusion criteria for Parts A and B as applicable
  • Part D only: have completed the 52 weeks (Week 24 to Week 76) of participation in Part C of the study without permanent study drug discontinuation and have not completed the Follow-Up Visit (approximately 28 days after the last dose of study drug)

Exclusion criteria

Exclusion Criteria:

  • Must not have received any parenteral administered by intra-articular, intramuscular (IM), or intravenous (IV) injection within 6 weeks prior to baseline
  • Must not be concomitantly using non-steroidal anti-inflammatory drugs (NSAIDS), unless you are on a stable dose within the last 4 weeks
  • Must not have received any prior biologic disease modifying anti-rheumatic drug (DMARD) therapy [such as Tumor necrosis factor-alpha (TNFα), interleukin (IL)-1, IL-6, T-cell or B-cell target therapies)
  • Must not have used DMARDs other than methotrexate (MTX), hydroxychloroquine, or sulfasalazine within the last 8 weeks
  • Must not have used leflunomide within the last 12 weeks and have not received cholestyramine to speed up the elimination of leflunomide from your body
  • Must not have previously been randomized, completed or withdrawn from this study or any other study investigating LY3009104
  • Must not have received prior treatment with an oral JAK inhibitor
  • Must not have a current or recent (within the last 30 days) viral, bacterial, fungal, or parasitic infection
  • Must not have had a serious infection (for example, pneumonia, cellulitis, or bone or joint infections) or atypical mycobacterial infection within the last 6 months
  • Must not have had symptomatic herpes zoster or herpes simplex infection within the last 90 days or have a history of disseminated/complicated herpes zoster
  • Must not have evidence of (HIV) and/or positive human HIV antibodies
  • Must not have evidence of virus (HCV) or active
  • Must not have evidence or suspicion of active or latent tuberculosis (TB)
  • Must not have another serious disorder or illness
  • Must not be exposed to a within the last 12 weeks
  • Must not have donated more than 500 milliliters (mL) of blood within the last month
  • Must not have had surgery on a joint that is to be assessed in the study within the last 2 months, or will require such during the study
  • Must not be currently enrolled in, or discontinued within the last 30 days from a clinical trial involving an drug or device or off-label use of a drug, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Presence of significant uncontrolled cerebro-cardiovascular [for example (eg), myocardial infarction (MI), unstable angina (UA), unstable arterial hypertension, severe heart failure or cerebrovascular accident], respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematologic or neuropsychiatric disorders, or abnormal laboratory values that in the opinion of the investigator pose an unacceptable risk to the participant if study drug would be administered
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    1 mg LY3009104 once daily

    Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.

    Drug: LY3009104 · Drug: Methotrexate

  • Experimental
    2 mg LY3009104 once daily

    Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.

    Drug: LY3009104 · Drug: Methotrexate

  • Experimental
    4 mg LY3009104 once daily

    Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.

    Drug: LY3009104 · Drug: Methotrexate

  • Experimental
    8 mg LY3009104 once daily

    Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.

    Drug: LY3009104 · Drug: Methotrexate

  • Placebo comparator
    Placebo once daily

    Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.

    Drug: Placebo · Drug: Methotrexate

  • Experimental
    2 mg LY3009104 twice daily

    (Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.

    Drug: LY3009104 · Drug: Methotrexate

Interventions

  • Administered orally

    Also known as: Janus Kinase (JAK)1/JAK2 Inhibitor, JAK1/2 Inhibitor, INCB028050, baricitinib

  • DrugPlacebo

    Administered orally

  • Administered orally as background therapy

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.

    Time frame: Baseline through Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.

    Time frame: Baseline through Week 12

  2. Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.

    Time frame: Baseline through Weeks 2, 4, 8, 12, 16, 20, 24

  3. Percentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.

    Time frame: Baseline through Weeks 76 and 128

  4. Percentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24

    ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.

    Time frame: Baseline through Weeks 2, 4, 8, 12, 16, 20, 24

  5. Percentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128

    ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.

    Time frame: Baseline through Weeks 76 and 128

  6. Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24

    ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.

    Time frame: Baseline through Weeks 2, 4, 8, 12, 16, 20, 24

  7. Percentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128

    ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.

    Time frame: Baseline through Weeks 76 and 128

  8. Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response

    ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.

    Time frame: Baseline through Week 12

  9. ACR Percent Improvement (ACR-N)

    ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.

    Time frame: Baseline through Week 12

  10. Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)

    TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.

    Time frame: Baseline, Weeks 12 and 24

  11. Mean Change From Baseline to Weeks 76 and 128 in TJC and SJC

    TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.

    Time frame: Baseline, Weeks 76 and 128

  12. Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Weeks 12 and 24

  13. Mean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Weeks 76 and 128

  14. Mean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)

    hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.

    Time frame: Baseline, Weeks 12 and 24

  15. Mean Change From Baseline to Weeks 76 and 128 in hsCRP

    hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.

    Time frame: Baseline, Weeks 76 and 128

  16. Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)

    ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.

    Time frame: Baseline, Weeks 12 and 24

  17. Mean Change From Baseline to Weeks 76 and 128 in ESR

    ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.

    Time frame: Baseline, Weeks 76 and 128

  18. Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain

    Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).

    Time frame: Baseline, Weeks 12 and 24

  19. Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain

    Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).

    Time frame: Baseline, Weeks 76 and 128

  20. Mean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Baseline, Weeks 12 and 24

  21. Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

    Time frame: Baseline, Weeks 76 and 128

  22. Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24

    EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).

    Time frame: Baseline through Weeks 12 and 24

  23. Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128

    EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).

    Time frame: Baseline, Weeks 76 and 128

  24. Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24

    Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP \[milligrams per liter (mg/L)\], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.

    Time frame: Baseline through Weeks 12 and 24

  25. Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.

    Time frame: Baseline through Weeks 76 and 128

  26. Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness

    The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.

    Time frame: Baseline, Weeks 4, 8, 12

  27. Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.

    Time frame: Baseline, Week 12

  28. Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score

    The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant's perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 ("No pain") to 10 ("Pain as bad as you can imagine"). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.

    Time frame: Baseline, Week 12

  29. Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score

    The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.

    Time frame: Baseline, Week 12

  30. Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104

    Time frame: Baseline through 24 weeks

  31. Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104

    Time frame: Baseline through 24 weeks

  32. Mean Change From Baseline Through Week 12 in the ENSEMBLE Minimum Data Set 1.0

    Time frame: Baseline, 12 weeks

07

Results

Posted Apr 21, 2017

Participant flow

Part A (Weeks 0 Through 12)
Participant flow — Part A (Weeks 0 Through 12)
Milestone1 Milligrams (mg) LY3009104 QD - Part A2 mg LY3009104 QD - Parts A and B4 mg LY3009104 QD - Parts A and B8 mg LY3009104 QD - Parts A and BPlacebo QD - Part A2 mg LY3009104 BID - Part B4 mg LY3009104 QD - Part B4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Started495252509800000
Received at least 1 dose of study drug495252509800000
Completed445150498200000
Not completed51211600000
Withdrew: Adverse event1111500000
Withdrew: Entry criteria not met0000400000
Withdrew: Lack of efficacy2000100000
Withdrew: Physician decision0010200000
Withdrew: Protocol violation0000100000
Withdrew: Withdrawal by subject2000300000
Part B (Weeks 12 Through 24)
Participant flow — Part B (Weeks 12 Through 24)
Milestone1 Milligrams (mg) LY3009104 QD - Part A2 mg LY3009104 QD - Parts A and B4 mg LY3009104 QD - Parts A and B8 mg LY3009104 QD - Parts A and BPlacebo QD - Part A2 mg LY3009104 BID - Part B4 mg LY3009104 QD - Part B4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Started051504906363000
Completed050484505957000
Not completed0124046000
Withdrew: Adverse event0010010000
Withdrew: Lack of efficacy0101000000
Withdrew: Lost to follow-up0001001000
Withdrew: Withdrawal by subject0012034000
Withdrew: Entry criteria not met0000001000
Part C (Weeks 24 Through 76)
Participant flow — Part C (Weeks 24 Through 76)
Milestone1 Milligrams (mg) LY3009104 QD - Part A2 mg LY3009104 QD - Parts A and B4 mg LY3009104 QD - Parts A and B8 mg LY3009104 QD - Parts A and BPlacebo QD - Part A2 mg LY3009104 BID - Part B4 mg LY3009104 QD - Part B4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Started00000001086132
Completed0000000925324
Not completed00000001688
Withdrew: Adverse event0000000822
Withdrew: Withdrawal by subject0000000622
Withdrew: Lost to follow-up0000000211
Withdrew: Lack of efficacy0000000020
Withdrew: Death0000000001
Withdrew: Entry criteria not met0000000001
Withdrew: Physician decision0000000001
Withdrew: Reason missing0000000010
Part D (Weeks 76 Through 128)
Participant flow — Part D (Weeks 76 Through 128)
Milestone1 Milligrams (mg) LY3009104 QD - Part A2 mg LY3009104 QD - Parts A and B4 mg LY3009104 QD - Parts A and B8 mg LY3009104 QD - Parts A and BPlacebo QD - Part A2 mg LY3009104 BID - Part B4 mg LY3009104 QD - Part B4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Started0000000794718
Completed0000000764017
Not completed0000000371
Withdrew: Lost to follow-up0000000130
Withdrew: Withdrawal by subject0000000121
Withdrew: Adverse event0000000120

Outcome measures

PrimaryPercentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12
percentage of participants4 or 8 mg LY3009104Placebo
Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 127641
Statistical analysis
  • 4 or 8 mg LY3009104 vs Placebo · Regression, Logistic · p = <0.001 (A priori p-value significance threshold: 1-sided ≤0.10)
SecondaryPercentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response
percentage of participants1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 12 - Model Based Dose Response54.6 (42.2 to 67.1)55.2 (42.3 to 67.6)74.3 (63.1 to 84.1)77.2 (65.9 to 86.7)42.1 (32.9 to 51.6)
SecondaryPercentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants treated) \* 100.

Time frame:
Baseline through Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR20 Responder Index Response Baseline Through Week 24
percentage of participants1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 22921424411
Week 44337605424
Week 84342677236
Week 125754757841
Week 16NA636764NA
Week 20NA717778NA
Week 24NA627572NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · Fisher Exact · p = 0.045 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · Fisher Exact · p = 0.088 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
SecondaryPercentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \* 100.

Time frame:
Baseline through Weeks 76 and 128
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR20 Response Baseline Through Weeks 76 and 128
percentage of participants4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Week 76 (n=108, 61, 32)716759
Week 128 (n=79, 47, 18)775772
SecondaryPercentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24

ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.

Time frame:
Baseline through Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR 50 Responder Index Response Baseline Through Week 24
percentage of participants1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 2042142
Week 4101029223
Week 8161033367
Week 123117354010
Week 16NA193844NA
Week 20NA274648NA
Week 24NA194654NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · Fisher Exact · p = 0.003 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · Fisher Exact · p = 0.162 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
SecondaryPercentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128

ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100.

Time frame:
Baseline through Weeks 76 and 128
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR50 Response Baseline Through Weeks 76 and 128
percentage of participants4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Week 76 (n=108, 61, 32)494144
Week 128 (n=79, 47, 18)583044
SecondaryPercentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24

ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.

Time frame:
Baseline through Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24
percentage of participants1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 2021200
Week 4241060
Week 84415220
Week 1212823202
Week 16NA82330NA
Week 20NA102126NA
Week 24NA102724NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · Fisher Exact · p = 0.017 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · Fisher Exact · p = 0.109 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
SecondaryPercentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128

ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \* 100.

Time frame:
Baseline through Weeks 76 and 128
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR70 Response Baseline Through Weeks 76 and 128
percentage of participants4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Week 76 (n=108, 61, 32)291825
Week 128 (n=79, 47, 18)281722
SecondaryPercentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response

ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR50 Responder is a participant who had ≥50% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥50% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR50 response = (number of ACR50 responders) / (number of participants analyzed) \* 100. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response
percentage of participants1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Percentage of Participants Who Achieved an ACR50 Response Baseline Through Week 12 - Model Based Dose Response26.5 (16.0 to 39.2)18.8 (9.9 to 29.7)34.4 (23.1 to 46.7)39.2 (27.1 to 52.2)12.0 (6.5 to 18.8)
SecondaryACR Percent Improvement (ACR-N)

ACR-N is a continuous measure of clinical, laboratory, and functional outcomes in RA that characterizes percentage (%) of improvement in disease activity from baseline based on ACR core set. This index was calculated as minimum of a) % of improvement in TJC, b) % of improvement in SJC, and c) third highest percentage of improvement of remaining 5 ACR core criteria: If ≥3 components of the 5 ACR core criteria were missing, then c) was set to missing; if any of 3 components a), b), or c) were missing, then ACR-N was set to missing. Percentage of improvement was truncated to a range of -100 to 100 to minimize impact of outliers (greater scores indicate greater % improvement) and negative scores indicate a decline. Data presented are model-based Bayesian posterior mean response rates with 95% credible interval.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of improvement
ACR Percent Improvement (ACR-N)
percentage of improvement1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
ACR Percent Improvement (ACR-N)17.30 (7.57 to 28.22)19.42 (8.74 to 29.25)28.59 (17.67 to 40.83)29.00 (17.67 to 41.47)10.97 (-0.39 to 21.64)
SecondaryMean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)

TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · number of joints
Mean Change From Baseline to Weeks 12 and 24 in Tender and Swollen Joint Counts (TJC and SJC)
number of joints1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
TJC - Week 12-8.4 ± 12.70-11.3 ± 13.50-12.2 ± 10.45-14.7 ± 12.97-7.6 ± 12.31
TJC - Week 24NA ± NA-12.4 ± 12.60-14.0 ± 9.54-17.5 ± 11.23NA ± NA
SJC - Week 12-8.1 ± 7.24-8.9 ± 9.03-9.6 ± 6.49-10.4 ± 8.88-6.7 ± 7.97
SJC - Week 24NA ± NA-10.0 ± 8.16-10.5 ± 6.42-12.2 ± 7.29NA ± NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.480 (P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.064 (P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.001 (P-value is for TJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.116 (P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.201 (P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.002 (P-value is for SJC - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Weeks 76 and 128 in TJC and SJC

TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint.

Time frame:
Baseline, Weeks 76 and 128
Reported as:
Mean · units on a scale
Mean Change From Baseline to Weeks 76 and 128 in TJC and SJC
units on a scale4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
TJC - Week 76 (n=108, 61, 32)-15.7 ± 11.26-16.0 ± 13.37-18.1 ± 12.06
TJC - Week 128 (n=79, 47, 18)-16.4 ± 11.01-15.3 ± 12.56-14.0 ± 13.68
SJC - Week 76 (n=108, 61, 32)-11.6 ± 6.40-12.9 ± 7.80-12.4 ± 7.67
SJC - Week 128 (n=79, 47, 18)-11.4 ± 6.81-12.4 ± 8.01-11.6 ± 6.23
SecondaryMean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Mean Change From Baseline to Weeks 12 and 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
units on a scale1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 12-0.35 ± 0.528-0.18 ± 0.524-0.33 ± 0.459-0.39 ± 0.497-0.10 ± 0.406
Week 24NA ± NA-0.18 ± 0.505-0.32 ± 0.506-0.44 ± 0.529NA ± NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.003 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.167 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.001 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Weeks 76 and 128
Reported as:
Mean · units on a scale
Mean Change From Baseline to Weeks 76 and 128 in HAQ-DI Score
units on a scale4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Week 76 (n=108, 61, 32)-0.34 ± 0.58-0.29 ± 0.53-0.55 ± 0.58
Week 128 (n=79, 47, 18)-0.31 ± 0.61-0.22 ± 0.56-0.30 ± 0.66
SecondaryMean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)

hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · mg/L
Mean Change From Baseline to Weeks 12 and 24 in High-Sensitivity C-Reactive Protein (hsCRP)
mg/L1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 12-6.14 ± 10.236-3.39 ± 19.409-7.06 ± 16.945-2.32 ± 32.5821.50 ± 34.107
Week 24NA ± NA-4.76 ± 18.695-4.95 ± 19.819-7.61 ± 17.548NA ± NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.016 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.108 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = 0.008 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.368 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Weeks 76 and 128 in hsCRP

hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation.

Time frame:
Baseline, Weeks 76 and 128
Reported as:
Mean · mg/L
Mean Change From Baseline to Weeks 76 and 128 in hsCRP
mg/L4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Week 76 (n=108, 61, 32)-3.9 ± 22.43-3.3 ± 14.28-2.9 ± 25.36
Week 128 (n=79, 47, 18)-6.8 ± 13.66-2.9 ± 21.88-8.2 ± 12.33
SecondaryMean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)

ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · mm/hr
Mean Change From Baseline to Weeks 12 and 24 in Erythrocyte Sedimentation Rate (ESR)
mm/hr1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 12 (n=44, 51, 50, 49, 83)-11.6 ± 14.45-6.4 ± 16.81-11.5 ± 17.28-13.9 ± 22.42-6.0 ± 19.49
Week 24 (n=0, 50, 48, 45, 0)NA ± NA-6.9 ± 13.89-9.2 ± 19.00-13.7 ± 21.62NA ± NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.039 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.458 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = 0.008 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.029 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Weeks 76 and 128 in ESR

ESR is a laboratory analyte that is an indicator of inflammation. Decreases represent reductions in inflammation.

Time frame:
Baseline, Weeks 76 and 128
Reported as:
Mean · mm/hr
Mean Change From Baseline to Weeks 76 and 128 in ESR
mm/hr4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Week 76 (n=108, 61, 32)-13.0 ± 18.84-7.4 ± 26.28-8.9 ± 23.12
Week 128 (n=79, 47, 18)-16.0 ± 18.74-8.5 ± 23.11-15.5 ± 23.07
SecondaryMean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain

Physician's and Patient's Assessments of Disease Activity (DA) assessed using a visual analog scale (VAS) that ranged from 0 to 100 millimeters (mm), where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis was also assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Mean Change From Baseline to Weeks 12 and 24 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain
units on a scale1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Physician's Assessment of DA - Week 12-23.9 ± 18.49-25.0 ± 20.81-30.4 ± 18.75-33.5 ± 19.49-19.0 ± 21.40
Physician's Assessment of DA - Week 24NA ± NA-27.8 ± 21.13-35.5 ± 17.72-37.8 ± 18.73NA ± NA
Patient's Assessment of DA - Week 12-24.9 ± 27.26-16.2 ± 22.43-25.4 ± 21.61-29.8 ± 21.20-10.3 ± 22.02
Patient's Assessment of DA - Week 24NA ± NA-16.9 ± 24.96-30.2 ± 21.85-30.0 ± 20.90NA ± NA
Patient's Assessment of Pain - Week 12-22.8 ± 27.39-14.2 ± 17.82-25.0 ± 19.22-25.3 ± 20.31-8.8 ± 22.77
Patient's Assessment of Pain - Week 24NA ± NA-14.7 ± 20.57-27.3 ± 22.11-26.9 ± 19.22NA ± NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.217 (P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.092 (P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Physician's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.072 (P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Patient's Assessment of DA - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.082 (P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Patient's Assessment of Pain - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain

Physician's and Patient's assessments of DA assessed using a VAS that ranged from 0 to 100 mm, where 0 indicated no arthritis activity and 100 indicated extremely active arthritis. Patient's assessment of pain due to arthritis assessed using a VAS that ranged from 0 (no pain) to 100 mm (worst possible pain).

Time frame:
Baseline, Weeks 76 and 128
Reported as:
Mean · units on a scale
Mean Change From Baseline to Weeks 76 and 128 in Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity and Patient's Assessment of Pain
units on a scale4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Physician Assessment of DA-Week 76 (n=108, 61, 32)-40.3 ± 19.15-32.3 ± 23.37-40.5 ± 21.44
Physician Assessment of DA-Week 128 (n=79, 47, 18)-39.5 ± 20.32-31.0 ± 25.54-34.0 ± 27.51
Patient Assessment of DA-Week 76 (n=108, 61, 32)-27.5 ± 26.49-27.5 ± 25.52-27.6 ± 24.11
Patient Assessment of DA-Week 128 (n=79, 47, 18)-27.9 ± 27.40-19.3 ± 29.72-27.6 ± 25.17
Patient Assessment of Pain-Week 76 (n=108, 61, 32)-25.1 ± 24.10-27.3 ± 24.24-23.4 ± 23.49
Patient Assessment of Pain-Week 128 (n=79, 47, 18)-24.2 ± 24.35-18.0 ± 28.85-22.3 ± 22.99
SecondaryMean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count-28 (TJC28), swollen joint count-28 (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity, and remission was DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Mean Change From Baseline to Weeks 12 and 24 in Disease Activity Score (DAS) Based on the 28 Diarthrodial Joint Count and CRP Level (DAS28-CRP)
units on a scale1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 12-1.47 ± 1.299-1.40 ± 1.210-2.09 ± 1.220-2.15 ± 1.273-0.98 ± 1.141
Week 24NA ± NA-1.53 ± 1.187-2.25 ± 1.054-2.47 ± 1.280NA ± NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.024 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.030 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Weeks 76 and 128 in DAS28-CRP

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.

Time frame:
Baseline, Weeks 76 and 128
Reported as:
Mean · units on a scale
Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP
units on a scale4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Week 76 (n=107, 61, 31)-2.47 ± 1.23-2.16 ± 1.28-2.68 ± 1.12
Week 128 (n=79, 47, 18)-2.56 ± 1.16-2.02 ± 1.23-2.35 ± 1.40
SecondaryPercentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24

EULAR28 categorizes clinical response based upon improvement since baseline in DAS modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: TJC28, SJC28, CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).

Time frame:
Baseline through Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Responders According to European League Against Rheumatism Responder Index Based on 28-joint Count (EULAR28) Baseline Through Weeks 12 and 24
percentage of participants1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Good Response - Week 122217464016
Moderate Response - Week 124363314635
No Response - Week 123519231449
Good Response - Week 24NA254246NA
Moderate Response - Week 24NA524232NA
No Response - Week 24NA231522NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · Cochran-Mantel-Haenszel · p = 0.120 (P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · Cochran-Mantel-Haenszel · p = 0.012 (P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 (P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 (P-value is for comparison of the superiority of the LY3009104 dose level vs. placebo for the ordinal levels of response - Week 12. A priori p-value significance threshold: 1-sided ≤0.10.)
SecondaryPercentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128

EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \>0.6 units but ≤1.2 units or post-baseline DAS28 score \>3.2 with improvement by \>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \>1.2 units).

Time frame:
Baseline, Weeks 76 and 128
Reported as:
Number · percentage of participants
Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128
percentage of participants4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Good Response - Week 76 (n=107, 61, 31)644155
Moderate Response - Week 76 (n=107, 61, 31)274639
No Response - Week 76 (n=107, 61, 31)8136
Good Response - Week 128 (n=79, 47, 18)654056
Moderate Response - Week 128 (n=79, 47, 18)304028
No Response - Week 128 (n=79, 47, 18)51917
SecondaryPercentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24

Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP \[milligrams per liter (mg/L)\], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.

Time frame:
Baseline through Weeks 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24
percentage of participants1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Low Disease Activity - Week 122223484019
Remission - Week 12141537224
Low Disease Activity - Week 24NA315046NA
Remission - Week 24NA153336NA
Statistical analysis
  • 1 mg LY3009104 vs Placebo · Fisher Exact · p = 0.409 (P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · Fisher Exact · p = 0.371 (P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · Fisher Exact · p = 0.007 (P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 1 mg LY3009104 vs Placebo · Fisher Exact · p = 0.033 (P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · Fisher Exact · p = 0.019 (P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · Fisher Exact · p = <0.001 (P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · Fisher Exact · p = 0.001 (P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryPercentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.

Time frame:
Baseline through Weeks 76 and 128
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128
percentage of participants4 mg LY3009104 QD - Parts C and D4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D
Low Disease activity - Week 76 (n=108, 61, 32)583844
Remission - Week 76 (n=108, 61, 32)522122
Low Disease activity - Week 128 (n=79, 47, 18)593656
Remission - Week 128 (n=79, 47, 18)472639
SecondaryMean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness

The Investigator asked participants about the duration of their morning stiffness (in minutes) in and around the joints and recorded the duration. The Investigator asked the participants about duration of morning stiffness on the day prior to the study visit to capture actual symptoms. If morning stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses.

Time frame:
Baseline, Weeks 4, 8, 12
Reported as:
Mean · minutes
Mean Change From Baseline Through Week 12 in Duration (Minutes) of Morning Stiffness
minutes1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Week 4 (n=47, 50, 50, 50, 94)-34.1 ± 70.49-27.0 ± 46.49-57.4 ± 149.00-25.5 ± 126.13-22.5 ± 63.61
Week 8 (n=46, 50, 50, 50, 86)-41.2 ± 85.45-31.1 ± 45.80-67.8 ± 138.02-53.8 ± 101.76-25.5 ± 67.39
Week 12 (n=48, 51, 50, 50, 97)-49.5 ± 72.80-30.7 ± 47.41-75.0 ± 142.04-62.7 ± 88.27-33.9 ± 91.79
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.015 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.073 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for Week 12. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains (physical functioning, bodily pain, role limitations due to physical problems and also emotional problems, general health, mental health, social functioning and vitality) and 2 component scores (PCS and MCS). The PCS score consisted of physical functioning, bodily pain, role-physical, and general health scales. The MCS score consisted of social functioning, vitality, mental health, and role-emotional scales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline to Week 12 in Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
units on a scale1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
PCS6.66 ± 8.0744.15 ± 7.6807.07 ± 7.3787.00 ± 9.0543.22 ± 6.733
MCS2.54 ± 11.9831.89 ± 6.8692.39 ± 7.8983.03 ± 10.6750.88 ± 10.437
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.021 (P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.194 (P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.012 (P-value is for PCS. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.449 (P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.578 (P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = 0.140 (P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.266 (P-value is for MCS. A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score

The BPI-sf modified is a self-administered questionnaire developed for the rapid assessment of pain. The BPI-sf modified provides information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The questionnaire asks questions about pain relief, pain quality, and the participant's perception of the cause of pain. The BPI-sf modified uses a numeric rating scale from 0 ("No pain") to 10 ("Pain as bad as you can imagine"). Since pain can be quite variable over a day, the BPI-sf modified asked participants to rate their pain at the time of responding to the questionnaire (right now), and also at its worst, least and average over the last 24 hours.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score
units on a scale1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Mean Change From Baseline to Week 12 in Brief Pain Inventory Modified Short Form (BPI-sf Modified) Worst-Pain-in-the Past-24-hours Item Score-1.35 ± 2.547-0.67 ± 2.132-1.41 ± 1.813-1.54 ± 2.131-0.35 ± 2.136
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.005A priori p-value significance threshold: 2-sided ≤0.10.
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.135 (A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = <0.001 (A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.001 (A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryMean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score

The FACIT-F Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score
units on a scale1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104Placebo
Mean Change From Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) Score4.48 ± 10.4923.80 ± 9.1524.41 ± 8.6314.11 ± 9.9712.02 ± 8.941
Statistical analysis
  • 1 mg LY3009104 vs Placebo · ANCOVA · p = 0.203 (A priori p-value significance threshold: 2-sided ≤0.10.)
  • 2 mg LY3009104 vs Placebo · ANCOVA · p = 0.164 (A priori p-value significance threshold: 2-sided ≤0.10.)
  • 4 mg LY3009104 vs Placebo · ANCOVA · p = 0.018 (A priori p-value significance threshold: 2-sided ≤0.10.)
  • 8 mg LY3009104 vs Placebo · ANCOVA · p = 0.097 (A priori p-value significance threshold: 2-sided ≤0.10.)
SecondaryPopulation Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104
Time frame:
Baseline through 24 weeks
Reported as:
Geometric mean · nanomoles/Liter (nmol/L)
Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY3009104
nanomoles/Liter (nmol/L)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104
Population Pharmacokinetics (PK): Maximum Concentration at Steady State of Dosing (Cmax,ss) of LY300910436.5 ± 36.159.1 ± 21.3119.0 ± 20.5241.0 ± 22.9
SecondaryPopulation PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104
Time frame:
Baseline through 24 weeks
Reported as:
Geometric mean · nanomoles*hour/Liter (nmol*h/L)
Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104
nanomoles*hour/Liter (nmol*h/L)1mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104
Population PK: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3009104333 ± 61.7541 ± 38.01060 ± 37.02190 ± 45.6
SecondaryMean Change From Baseline Through Week 12 in the ENSEMBLE Minimum Data Set 1.0
Time frame:
Baseline, 12 weeks

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 mg LY3009104 QD - Part A—0/49 (0%)15/49 (30.6%)
2 mg LY3009104 QD - Part A—3/52 (5.8%)13/52 (25%)
4 mg LY3009104 QD - Part A—2/52 (3.8%)13/52 (25%)
8 mg LY3009104 QD - Part A—1/50 (2%)15/50 (30%)
Placebo QD - Part A—3/98 (3.1%)18/98 (18.4%)
2 mg LY3009104 BID Crossover- Part B—2/63 (3.2%)15/63 (23.8%)
4 mg LY3009104 QD Crossover- Part B—1/63 (1.6%)10/63 (15.9%)
2 mg LY3009104 QD - Part B—0/51 (0%)12/51 (23.5%)
4 mg LY3009104 QD - Part B—0/50 (0%)10/50 (20%)
8 mg LY3009104 QD - Part B—3/49 (6.1%)18/49 (36.7%)
4 mg LY3009104 QD - Part C—16/108 (14.8%)35/108 (32.4%)
4 to 8 mg LY3009104 QD Pre-Rescue - Part C—1/61 (1.6%)7/61 (11.5%)
4 to 8 mg LY3009104 QD Post-Rescue - Part C—6/61 (9.8%)25/61 (41%)
8 mg LY3009104 QD - Part C—6/32 (18.8%)16/32 (50%)
4 mg LY3009104 QD - Part D—5/79 (6.3%)24/79 (30.4%)
4 mg LY3009104 QD (4 to 8 mg Rescue)- Part D—3/47 (6.4%)13/47 (27.7%)
8/4 mg LY3009104 QD - Part D—0/18 (0%)10/18 (55.6%)
Follow-Up—2/159 (1.3%)5/159 (3.1%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
Event1 mg LY3009104 QD - Part A2 mg LY3009104 QD - Part A4 mg LY3009104 QD - Part A8 mg LY3009104 QD - Part APlacebo QD - Part A2 mg LY3009104 BID Crossover- Part B4 mg LY3009104 QD Crossover- Part B2 mg LY3009104 QD - Part B4 mg LY3009104 QD - Part B8 mg LY3009104 QD - Part B4 mg LY3009104 QD - Part C4 to 8 mg LY3009104 QD Pre-Rescue - Part C4 to 8 mg LY3009104 QD Post-Rescue - Part C8 mg LY3009104 QD - Part C4 mg LY3009104 QD - Part D4 mg LY3009104 QD (4 to 8 mg Rescue)- Part D8/4 mg LY3009104 QD - Part DFollow-Up
PneumoniaInfections and infestations0/491/520/520/500/980/630/630/510/500/490/1080/610/610/320/792/470/180/159
Herpes zosterInfections and infestations0/490/520/520/500/980/630/630/510/500/494/1080/610/611/321/790/470/180/159
Myocardial infarctionCardiac disorders0/490/520/520/500/980/630/630/510/500/490/1080/610/611/320/790/470/180/159
Ulcerative keratitisEye disorders0/490/520/520/500/980/630/630/510/500/490/1080/610/611/320/790/470/180/159
ColitisGastrointestinal disorders0/490/520/520/500/980/630/630/510/500/490/1080/611/611/320/790/470/180/159
Acute hepatitis bInfections and infestations0/490/520/520/500/980/630/630/510/500/490/1080/610/611/320/790/470/180/159
DehydrationMetabolism and nutrition disorders0/490/520/520/500/980/630/630/510/500/491/1080/610/611/320/791/470/180/159
PresyncopeNervous system disorders0/490/520/520/500/980/630/630/510/500/490/1080/610/611/320/790/470/180/159
GastroenteritisInfections and infestations0/490/520/520/500/980/630/630/510/500/491/1080/610/610/320/791/470/180/159
SyncopeNervous system disorders0/490/520/520/500/980/630/630/510/500/490/1080/610/610/320/791/470/180/159
Most frequent other events
Showing 10 of 35
Most frequent other events
Event1 mg LY3009104 QD - Part A2 mg LY3009104 QD - Part A4 mg LY3009104 QD - Part A8 mg LY3009104 QD - Part APlacebo QD - Part A2 mg LY3009104 BID Crossover- Part B4 mg LY3009104 QD Crossover- Part B2 mg LY3009104 QD - Part B4 mg LY3009104 QD - Part B8 mg LY3009104 QD - Part B4 mg LY3009104 QD - Part C4 to 8 mg LY3009104 QD Pre-Rescue - Part C4 to 8 mg LY3009104 QD Post-Rescue - Part C8 mg LY3009104 QD - Part C4 mg LY3009104 QD - Part D4 mg LY3009104 QD (4 to 8 mg Rescue)- Part D8/4 mg LY3009104 QD - Part DFollow-Up
BronchitisInfections and infestations1/491/522/521/503/981/632/632/510/500/499/1080/613/615/323/792/471/181/159
NasopharyngitisInfections and infestations0/490/522/521/502/981/630/630/510/502/492/1080/614/611/327/792/472/180/159
Urinary tract infectionInfections and infestations2/492/522/522/504/981/631/632/511/502/4912/1081/615/613/323/791/470/182/159
Upper respiratory tract infectionInfections and infestations0/491/521/521/502/982/634/632/511/502/499/1081/616/611/323/792/471/180/159
HypercholesterolaemiaMetabolism and nutrition disorders2/492/520/522/502/981/630/630/510/504/491/1081/611/610/321/790/471/180/159
HypertensionVascular disorders0/490/520/520/501/980/630/631/514/501/491/1080/610/610/320/790/470/180/159
Alanine aminotransferase increasedInvestigations0/491/520/521/503/980/630/631/511/501/491/1080/610/610/321/793/470/180/159
Low density lipoprotein increasedInvestigations0/490/521/521/502/984/631/631/511/503/490/1080/610/610/323/790/470/180/159
AnaemiaBlood and lymphatic system disorders0/490/522/520/500/981/630/630/510/501/490/1081/610/612/321/791/470/180/159
Irritable bowel syndromeGastrointestinal disorders0/490/520/520/500/980/630/630/510/500/490/1080/610/612/320/790/470/180/159

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
Mean53.1 ± 11.0750.7 ± 13.1252.5 ± 10.4252.7 ± 10.9149.2 ± 12.1551.2 ± 11.71
Sex: Female, Male
Sex: Female, Male(Participants)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
Female4244374185249
Male781591352
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
Hispanic or Latino10712111656
Not Hispanic or Latino3641363678227
Unknown or Not Reported3443418
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
American Indian or Alaska Native4332719
Asian88791547
Native Hawaiian or Other Pacific Islander000000
Black or African American0122611
White3740403770224
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
United States161616163195
Hungary3332213
Czech Republic4363723
Mexico78881647
Poland45671133
Ukraine6653929
Croatia010157
Romania2213311
India78771443
Duration of Rheumatoid Arthritis
Duration of Rheumatoid Arthritis(years)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
Mean5.45 ± 3.8855.53 ± 4.3775.28 ± 4.4666.63 ± 5.0485.40 ± 4.2835.62 ± 4.401
Tender Joint Counts (TJC)
Tender Joint Counts (TJC)(number of joints)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
Mean21.4 ± 10.9023.0 ± 12.6019.9 ± 12.7124.4 ± 13.7622.2 ± 12.0622.2 ± 12.38
Swollen Joint Counts (SJC)
Swollen Joint Counts (SJC)(number of joints)1 mg LY30091042 mg LY30091044 mg LY30091048 mg LY3009104PlaceboTotal
Mean15.2 ± 6.5517.0 ± 9.3214.8 ± 7.5416.1 ± 7.9215.8 ± 8.6415.8 ± 8.13

2 further baseline measures are reported on the registry.

08

Study locations

68 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paradise Valley, Arizona 85253, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peoria, Arizona 85381, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Covina, California 91723, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Maria, California 93454, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Westlake Village, California 91361, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aventura, Florida 33180, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boca Raton, Florida 33432, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daytona Beach, Florida 32117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gainesville, Florida 32607, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jupiter, Florida 33458, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Mary, Florida 32746, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Melbourne, Florida 32901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Naples, Florida 34102, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32804, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palm Harbor, Florida 34684, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vero Beach, Florida 32960, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Bend, Indiana 46601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lexington, Kentucky 40504, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, Maryland 21045, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Flowood, Mississippi 39216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Louis, Missouri 63117, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lincoln, Nebraska 68516, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freehold, New Jersey 07728, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toms River, New Jersey 08755, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Success, New York 11042, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Middleburg Heights, Ohio 44130, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toledo, Ohio 43606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Duncansville, Pennsylvania 16635, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75231, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77008, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osijek, 31000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zagreb, 10000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ceska Lipa, 470 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hlucin, 748-01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hostivice, 253-01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hustopece, 693 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 128 50, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zlin, 760 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1027, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Debrecen, 4032, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kistarcsa, 2143, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Veszprem, 8200, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ahmedabad, 532004, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyderabaad, 500082, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pune, 411007, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trivandrum, 695011, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cuauhtemoc, 06090, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44158, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leon, 37000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Luis Potosi, 78200, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Czestochowa, 42-200, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elblag, 82-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krakow, 30-349, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 60-773, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torun, 87-100, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-507, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bacau, 600114, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 10584, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cluj-Napoca, 400006, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Galati, 800587, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iasi, 700656, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kiev, 03151, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyiv, 01601, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Simferopol, 95017, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ternopil, 46002, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vinnytsya, 21018, Ukraine
09

References and documents

Publications

  • Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. PubMed 34706874 ↗
  • Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6. No abstract available. PubMed 30842122 ↗
  • Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W. MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. J Rheumatol. 2019 Aug;46(8):887-895. doi: 10.3899/jrheum.171469. Epub 2019 Jan 15. PubMed 30647190 ↗
  • Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. PubMed 29463520 ↗
  • Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161. Epub 2017 Aug 15. PubMed 28811354 ↗
  • Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27. PubMed 25431052 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Dec 2011 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 5 years 4 months after primary completion. A results delay was requested in Feb 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2010
First posted
Aug 19, 2010
Start
Oct 2010
Primary completionActual
Dec 2011
CompletionActual
Mar 2014
Results delay requested
Feb 10, 2012
Results first posted
Apr 21, 2017
Last update
Jun 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01185353
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 19, 2010
Start date
Oct 2010
Primary completion
Dec 2011
Completion
Mar 2014
Results posted
Apr 21, 2017
Last update
Jun 16, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion